Presented by
Management Forum
Drafting successful pharmaceutical patents is complex and there are many pitfalls and risks to be aware of. You need to ensure you’re maximising the protection for your, and your client’s, pharmaceutical inventions thorough both primary and secondary pharmaceutical patents.
13-16 June 2023
+ 6-9 November 2023
from £999
The highly complex area of pharmaceutical patents is looked at in detail in this course. The expert faculty will take you through the key differences between the European and US systems and how these can impact your patents. They will explore the latest strategies and give you useful insights and practical solutions to your drafting issues. By understanding the importance of aligning your patent and regulatory strategies, you will improve your pharmaceutical claim drafting skills to the best advantage.
The practical claim drafting exercises included in the course will give you an opportunity to get to grips with the information in a safe environment and under the guidance of the trainers. They will help embed what you have learnt so that it can be taken back to the workplace and put into practice. As well as receiving inside knowledge and top tips and advice from the highly experienced professionals from industry and private practice, the course also provides a valuable opportunity to network with others in similar roles from different companies. By attending, you can discuss your challenges with colleagues and our expert faculty and find solutions to your questions.
Key topics covered in this intensive training programme include:
This course is part of our collection of IP & Patents Training Courses.
13-16 Jun 2023
6-9 Nov 2023
Dr. Amanda Murphy is a Partner in Finnegan’s Washington, DC Office and focuses her practice on strategic client counseling, portfolio management, and patent prosecution for a range of clients, including small startup companies, research foundations, and large biotechnology and pharmaceutical companies.
Amanda provides patentability opinions, prepares new patent applications, prosecutes U.S. and foreign applications, and represents appellants before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO). She has experience in prosecuting inter partes and ex parte reexamination applications, reissue applications, and patent term extension applications for approved pharmaceuticals, including obtaining supplemental protection certificates in Europe. In addition to her patent counseling and prosecution practice, Amanda also routinely represents petitioners and patent owners in inter partes review (IPR) and post grant review (PGR) proceedings before the PTAB. As part of that practice, Amanda works with experts to develop technical and legal bases for challenging or defending issued patents, and manages the preparation of substantive written submissions. She also provides strategic advice and pre-litigation analysis and prepares freedom-to-operate, enforceability, and infringement opinions.
13-16 Jun 2023
With experience handling patent portfolios for a broad range of clients from SME’s and universities to large multinationals, Victoria is skilled at providing customized advice to meet clients’ varying commercial needs. She is well-versed in a wide variety of chemical technologies including pharmaceutical products, agrochemicals, nutraceuticals, CFC replacements, fibers, and catalysis. Having worked on numerous global patent families she is well-practised in both developing and implementing a worldwide prosecution strategy that meets the requirements of local patent offices and the needs of clients.
Victoria is passionate about diversity in the profession and to this end has hosted events in collaboration with IP inclusive and ChIPs to support women in the workplace.
Before joining the patent profession, Victoria completed a DPhil at the University of Oxford in the area of carbohydrate chemistry and diabetes research, with the publication of 30 research papers. She subsequently worked as a post-doctoral researcher at Imperial College London, focussing on neglected tropical diseases.
13-16 Jun 2023
Alissa Lipton’s practice involves representing biotechnology and pharmaceutical companies in patent proceedings in district courts, before the U.S. Court of Appeals for the Federal Circuit, and before the U.S. Patent and Trademark Office (USPTO). Her practice also involves strategic client counseling, including due diligence and opinion work, and portfolio management.
Alissa has over a decade of experience representing companies in patent litigation, from pre-litigation analysis through appeal to the Federal Circuit. She also provides strategic counsel to clients in technologies including therapeutic antibodies, CRISPR, antisense technologies, diagnostics, and small molecules. Alissa’s practice includes due diligence, freedom-to-operate, enforceability, and infringement assessments.
Alissa served at the Federal Circuit as a law clerk for the Honorable Alvin A. Schall. She has represented veterans before the U.S. Court of Appeals for Veterans Affairs.
13-16 Jun 2023
Victoria entered the patent profession in 2009 and joins Finnegan having previously worked for two large UK firms. She has acquired extensive experience in a broad range of life sciences subject matter. Her areas of interest include antibody technologies, antisense therapeutics, blood products, vaccines, gene manipulation, and stem cell culture methods.
Victoria enjoys all aspects of prosecution, including drafting, filing, examination, and grant procedures. She has experience with oppositions and appeals, representing both patentee and opponent at Oral Proceedings before the European Patent Office (EPO). She has managed large, complex portfolios protecting high-value pharmaceuticals. Victoria has experience prosecuting supplementary protection certificates and has been involved in litigation proceedings before the UK High Court.
Victoria has a first-class degree in Biomedical Sciences from The University of Sheffield and a Ph.D. from University College London. She conducted research at the Institute of Child Health at Great Ormond Street Hospital, where she focused on the genetic interactions underlying two congenital syndromes.
13-16 Jun 2023
Maeve O’Flynn is a European and UK patent attorney with more than a decade of in-house experience, having worked at some of the world’s largest multinational corporations in the oil and chemical industries. She has worked for a range of clients, from startups to multinationals, covering diverse technologies such as cosmetics, sustainable chemistry, and catalysis.
Maeve has helped clients develop commercially relevant intellectual property strategies. This includes developing and managing global patent portfolios, provisioning advice regarding trade secrets and defensive publications, and negotiating collaboration and licensing agreements.
Maeve has extensive experience preparing and prosecuting patent applications, from the initial invention harvesting sessions through to achieving allowance. She works with clients to assess and value their patent portfolios, and to develop filing strategies that support their commercial aims. She also represents clients at oral proceedings before the European Patent Office, representing both patentee and opponent.
NEW higher discounts for multiple bookings - bring your colleagues to make your training budget go further:
Please contact us for pricing if you are interested in booking 5 or more delegates
13-16 June 2023
Live online
13:30-17:00 UK (London) (UTC+01)
14:30-18:00 Paris (UTC+02)
08:30-12:00 New York (UTC-04)
Course code 12165
Not ready to book yet?
for 7 days, no obligation
6-9 November 2023
Live online
13:30-17:00 UK (London) (UTC+00)
14:30-18:00 Paris (UTC+01)
08:30-12:00 New York (UTC-05)
Course code 12398
Until 02 Oct
Not ready to book yet?
for 7 days, no obligation
* Early booking discounts may not be combined with other discounts or offers. As such, the discounts for 2nd/3rd/4th delegates are based on the full price.
A very good webinar overall and felt very worthwhile. I am really glad that I attended. After the first day the sessions were livelier, and the polls added a little extra dimension to recap and tease out some of the points made in the presentations. The discussion between the EU and US based presenters on points of divergence worked really well and made the sessions less static and more engaging.
Nov 1 2022
Angela King
Patent Attorney, Croda Europe Limited
Denmark
United Kingdom
Finland
Sweden
Brazil
Germany
Hungary
Portugal
Switzerland
2 days
Typical duration
Pricing from:
We can customise this course to your requirements and deliver it on an in-house basis for any number of your staff or colleagues.
Contact our in-house training experts Aleksandra Beer and Yesim Nurko to discuss your requirements:
Multiple colleagues? See above for details of our discounts for 2, 3, or 4 delegates. For more, talk to one of our training experts to discuss how to: